Rinvoq (Upadacitinib) for Eczema

Overview
Rinvoq is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating people 12 years and older with refractory, moderate to severe atopic dermatitis (the most common subtype of eczema) that isn’t well controlled with other systemic drugs, including biologics, or when those treatments aren’t recommended. Rinvoq is also known by its drug name, upadacitinib.

Rinvoq is a Janus kinase (JAK) inhibitor. It’s believed to work by blocking Janus kinase enzymes, which lead to inflammation for people with atopic dermatitis. It’s not recommended for use with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.

How do I take it?
Rinvoq is taken once a day in the form of an extended-release tablet.

Side effects
The FDA-approved label for Rinvoq lists common side effects in people with atopic dermatitis including upper respiratory infections, flu, shingles, acne, cold sores, headache, cough, allergic reactions, nausea, fever, and weight gain.

Rare but serious side effects listed for Rinvoq include life-threatening infections including tuberculosis, lymphomas, blood clots, gastrointestinal tears, and fetal harm during pregnancy. Retinal detachment has also occurred in people with atopic dermatitis taking Rinvoq.

For more details about this treatment, visit:

Rinvoq — AbbVie
https://www.rinvoq.com/

Rinvoq Prescribing Information
https://www.rxabbvie.com/pdf/rinvoq_pi.pdf